Tvardi Therapeutics (TVRD)

• Market cap: $42.7M
• 1 day: 7.57%
• 5 days: 11.25%
• 1 month: 6.06%
• 3 months: -89.41%
• 6 months: -79.44%
• Year to date: 11.52%
• 1 year: -68.07%
• 5 years: -99.23%
• 10 years: -99.07%
• Sector: Healthcare
• Industry: Biotechnology

About: Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.